New hope for recurrent ovarian cancer: Triple-Drug combo trial launches
NCT ID NCT07261683
First seen Jan 05, 2026 · Last updated Jun 13, 2026 · Updated 22 times
Summary
This study tests a combination of three drugs—weekly paclitaxel (or nab-paclitaxel), pembrolizumab, and mirabegron—in adults whose ovarian cancer has returned. The main goal is to see if this treatment shrinks tumors and to check for side effects. About 20 participants will take the drugs and visit the clinic every two months for checkups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Obstetrics and Gynecology Hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200090, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.